Company: MIRA
Filing Date: 2025-06-17
Form Type: PREM14A
Source: 0001641172-25-015340
Chunk: 172

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-06-17
Form: PREM14A
Chunk 172
---
 and group counseling—are frequently integrated to help patients address emotional eating, set realistic goals, and sustain healthy habits.

While these approaches form the foundation of obesity treatment, alone, they often produce modest weight loss (5–10% of body weight) and require continuous engagement, which many patients struggle to maintain. This gap has created space for pharmacological and procedural interventions.

Pharmacological Treatments

In recent years, anti-obesity medications (AOMs) have emerged as transformative options for individuals unable to achieve or maintain weight loss through lifestyle changes alone. Historically, pharmacotherapy for obesity has had limited efficacy and significant safety concerns. However, the landscape has shifted dramatically with introducing GLP-1 receptor agonists and other hormone-targeting drugs that regulate appetite and satiety with improved safety profiles.

| Moore Financial Consulting |

| SKNY Pharmaceuticals, Inc. | April 2025    |
| Valuation                  | Page 12 of 25 |

Several medications have been approved for weight management:

| ● | Semaglutide                                                        
 (Ozempic, Wegovy): A GLP-1 receptor agonist that promotes satiety. |

| ● | Tirzepatide                                                                                  
 (Zepbound, Mounjaro): A dual GIP and GLP-1 receptor agonist. Clinical trials have shown that 
 participants taking the highest dose of Zepbound lost an average of 48 lbs over 72 weeks.    |

| ● | Liraglutide                                                           
 (Saxenda): Another GLP-1 receptor agonist used for weight management. |

These medications are typically prescribed for individuals with a BMI ≥ 30 or ≥ 27 with weight-related comorbidities and are used alongside lifestyle interventions.

The most significant recent advancement in pharmacological treatment is glucagon-like peptide-1 (GLP-1) receptor agonists, which mimic the effects of the GLP-1 hormone, promoting insulin secretion, delaying gastric emptying, and inducing a feeling of fullness. Leading medications include:

| ● | Wegovy                                                                                    
 (semaglutide): The FDA approved Wegovy in 2021 for chronic weight management. In clinical 
 trials, it demonstrated an average weight loss of 15% of body weight. It is administered  
 via weekly subcutaneous injection.                                                        |

| ● | Ozempic                                                                                   
 (semaglutide): Originally developed for type 2 diabetes, Ozempic is widely used off-label 
 for weight loss and has surged in